Trade Jazz Pharmaceuticals

Jazz Pharmaceuticals BC (merger of Jazz Pharmaceuticals, Azur Pharma PLC) is a biopharmaceutical company based in Ireland. Founded in 2003. One of the company's most important products is the U.S. Food and Drug Administration (FDA) approved xyrem (sodium oxybate), sodium salt from a naturally occurring neurotransmitter γ hydroxybutyric acid (GHB). In 2017, Xyrem's net product sales amounted to $1.187 billion, representing 74% of the company's total net product sales. In 2019, Jazz was granted FDA approval to market Sunosi with indications for the treatment of excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). in 2007, the company pleaded guilty to felony charges related to the illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research Division and the American Pharmaceutical Manufacturer (PhRMA). on February 18 2010, the FDA approved the application of a new drug for JZP-6 (sodium oxybate) to treat fibromyalgia. The following December, a new patent was issued for Sodium Oxybate.On September 19, 2011, Jazz Pharmaceuticals and Azur Pharma PLC agreed to the merger. On April 26, 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in significant payments). In September, the company successfully sold its women's health business to Meda for $95 million. In December, the company began a clinical trial of venous Erwinaze in patients with acute lymphocytes Leukemia.In January 2014, the company announced that it You will get rare pharmaceutical developer Gentium SpA and its main producer Defitelio for $1 billion. In May 2016, the company announced that it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its largest acquisition to date, with Celator Pharmaceuticals being purchased for $1.5 billion. As a result, Jazz obtained the rights to the breakthrough treatment of Vyxeos (daunorubicin lipocycland citarapine) for the treatment of acute myeloid leukemia. In August 2019, the company announced that it would acquire Cavillin for up to $310 million.